IMBRUVICA

Product Overview

About IMBRUVICA

IMBRUVICA (ibrutinib) is a prescription medication used to treat certain types of blood cancers, including mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and chronic lymphocytic leukemia (CLL) with 17p deletion or TP53 mutation.

Key Benefits & Uses

• Treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy.
• Treatment of Waldenström's macroglobulinemia (WM).
• Treatment of chronic lymphocytic leukemia (CLL) with 17p deletion or TP53 mutation.
• Treatment of CLL/SLL in the absence of 17p deletion or TP53 mutation.

Active Ingredient & Action

IMBRUVICA contains the active ingredient ibrutinib, a kinase inhibitor that targets the Bruton's tyrosine kinase (BTK) enzyme. By inhibiting BTK, ibrutinib blocks the activation of B cells, leading to the reduction of tumor cell growth and proliferation.

Important Notes

IMBRUVICA is available in capsule form and should be taken orally once daily. It is essential to follow the prescribed dosage and schedule to achieve optimal results. Patients should inform their healthcare provider about any medical history, including bleeding disorders, or if they are taking any other medications. Common side effects may include fatigue, diarrhea, and bruising.